Celltrion Remsima Becomes Korea's No. 1 Blockbuster Drug...Korea Pharmaceutical Bio Association also welcomes and congratulates messages
Feb 27, 2025
|
In a commentary, the association said, "It is a valuable achievement 22 years after LG Chem's antibiotic Factive received its first approval from the U.S. FDA in 2003 and entered the global market in earnest. Remsima, the world's first antibody biosimilar and has established itself as a global autoimmune disease treatment with product approval in more than 100 countries, has made a new history." He then encouraged that the birth of Korean blockbuster No. 1 will be a very meaningful milestone in the history of the Korean pharmaceutical bio industry, and at the same time a turning point in the leap that gives the industry great confidence in the whole industry.
According to Celltrion's preliminary annual performance last year on a consolidated basis announced on the 25th, its main product, Remsima, recorded 1.268 trillion won, or 35.6% of last year's total sales (KRW 3.5573 trillion). As a result, it won the title of 'Global Blockbuster', a drug with annual sales of more than KRW 1 trillion.
An official from Celltrion said, `We will not settle for the success of Remsima, but will accelerate the launch of subsequent biosimilars, including Remsima SC, and further successfully promote the development of new drugs such as ADC and multiple antibodies to do our best to create second and third Remsima.'
This article was translated by Naver AI translator.
